Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Preferred Stock Liabilities (2019 - 2020)

Keros Therapeutics filings provide 2 years of Preferred Stock Liabilities readings, the most recent being $55.8 million for Q1 2020.

  • On a quarterly basis, Preferred Stock Liabilities rose 512.57% to $55.8 million in Q1 2020 year-over-year; TTM through Mar 2020 was $55.8 million, a 512.57% increase, with the full-year FY2019 number at $19.9 million, changed N/A from a year prior.
  • Preferred Stock Liabilities hit $55.8 million in Q1 2020 for Keros Therapeutics, up from $19.9 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $55.8 million in Q1 2020 to a low of $9.1 million in Q1 2019.